Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

The promotional effort from Ferring features bladder cancer survivors sharing the news of a new treatment option.

Cretostimogene is an oncolytic immunotherapy with dual mechanism of action: viral replication leading to tumor lysis and release of granulocyte-macrophage colony stimulating factor.

Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials ...

Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 ...

The median duration of response (DOR) exceeds 28 months and is ongoing, demonstrating the durability of cretostimogene's ...

Learn more about the role of Tuberculosis in cancer and how a simple vaccine supports the immune system to fight it.

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle ...

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...

Cretostimogene treatment shows best-in-class durability of response for BCG-unresponsive non-muscle invasive bladder cancer ...

NANTONG, China and MELBOURNE, Australia I March 24, 2025 I Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA ...

Investigators employed artificial intelligence to characterize tissue samples of high-risk NMIBC that were likely to recur or progress after treatment with intravesical bacillus Calmette-Guérin (BCG).